Alta Partners and Healthcare Ventures led the round as part of an investor syndicate that included New Enterprise Associates and Polaris Venture Partners. The company will use the funds to progress its drug discovery portfolio.
Maxine Gowen, president and CEO of Trevena, said: “Trevena’s mission will be to utilize a state of the art approach to discover and develop novel GPCR-targeted medicines for patients.”